All In Biotech

Free tool

FAERS Monitor: Margenza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761150 or its brand name (Margenza, Margetuximab-Cmkb). Reports on generic versions are filed under their own applications.

Reports

27

Serious

14

52% of reports

Hospitalization

3

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death5
  • disease progression5
  • chills3
  • infusion related reaction2
  • abdominal pain1
  • alopecia1
  • anaphylactic reaction1
  • asthenia1
  • blood pressure decreased1
  • cardiac disorder1
  • constipation1
  • diarrhoea1
  • drug ineffective1
  • drug intolerance1
  • fatigue1

Reports by year received

View as table
YearReports
20218
202212
20234
20241
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,132 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal532.914.9125
infusion related reaction223.56.224
chillsSignal319.96.937
anaphylactic reaction114.12.13
blood pressure decreased111.71.72
cardiac disorder18.31.21
drug intolerance18.11.21
deathSignal54.52.011
alopecia14.00.60
constipation13.60.50
abdominal pain13.30.50
asthenia12.10.30
diarrhoea11.20.20
fatigue11.00.10
drug ineffective10.60.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.